News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has been trending somewhat positive on Thursday, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 44.6223552919683 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
CATB has been the topic of a number of research reports. CIBC restated an “outperform” rating and set a $7.00 price target (up previously from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research report on Thursday, November 16th. Oppenheimer raised their price objective on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research note on Thursday, October 5th. Citigroup reaffirmed a “hold” rating and set a $1.50 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday, September 29th. Finally, Cowen reaffirmed a “market perform” rating and set a $2.00 price objective on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $4.82.
Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded up $0.05 during trading hours on Thursday, hitting $1.57. The stock had a trading volume of 284,400 shares, compared to its average volume of 366,400. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $5.51. The company has a market capitalization of $36.93 and a PE ratio of -1.04.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.02. The company had revenue of $0.25 million for the quarter. research analysts predict that Catabasis Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://transcriptdaily.com/2018/01/04/catabasis-pharmaceuticals-catb-earns-news-impact-rating-of-0-11.html.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.